Edition:
United States

Biotec Pharmacon ASA (BIOTEC.OL)

BIOTEC.OL on Oslo Stock Exchange

11.80NOK
10:25am EDT
Change (% chg)

kr-0.05 (-0.42%)
Prev Close
kr11.85
Open
kr11.70
Day's High
kr11.80
Day's Low
kr11.65
Volume
13,604
Avg. Vol
118,982
52-wk High
kr18.40
52-wk Low
kr8.10

BIOTEC.OL

Chart for BIOTEC.OL

About

Biotec Pharmacon ASA is a Norway-based biopharmaceutical company that develops, manufactures and markets immune modulating compounds for the human health sectors and marine enzymes used in molecular biology. The Company focuses on new solutions within wound care, cancer therapies and other immune related disease areas. It has a... (more)

Overall

Beta: 0.00
Market Cap(Mil.): kr520.74
Shares Outstanding(Mil.): 43.94
Dividend: --
Yield (%): --

Financials

  BIOTEC.OL Industry Sector
P/E (TTM): -- 34.43 35.43
EPS (TTM): -0.41 -- --
ROI: -20.09 13.73 13.09
ROE: -20.09 14.71 14.22

BRIEF-Biotec Pharmacon Q1 EBITDA widens to loss NOK 3.5 mln

* Q1 revenue 17.3 million Norwegian crowns ($2.11 million)versus 12.3 million crowns year ago

Apr 19 2016

BRIEF-Biotec Pharmacon Q1 EBITDA widens to loss NOK 3.5 mln

* Q1 revenue 17.3 million Norwegian crowns ($2.11 million)versus 12.3 million crowns year ago

Apr 19 2016

BRIEF-Biotec Pharmacon unit awarded funding from Horizon2020 programme

* ArcticZymes, a subsidiary of Biotec Pharmacon has received 460,000 euros ($523,388.00) over the next four years in a project funded by the European Framework Programme for Research and Innovation, Horizon 2020 Source text for Eikon:

Apr 01 2016

BRIEF-Biotec BetaGlucans has entered into supply agreement for delivery of M-Glucan

* Subsidiary Biotec BetaGlucans AS has entered into a supplier agreement with a new feed company for deliveries of its beta-glucan product M-Glucan for use in animal health

Mar 11 2016

BRIEF-Biotec Pharmacon receives notice of allowance for Woulgan gel in USA

March 3 Biotec Pharmacon ASA : * Has received notice of allowance for Woulgan gel in the US Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Mar 03 2016

BRIEF-Biotec Pharmacon targets NOK 100 mln in revenues by 2018

* Targets 100 million Norwegian crowns ($11.71 million) in revenues, a cash positive operation and a strong product pipeline by 2018

Feb 11 2016

BRIEF-Biotec Pharmacon Q4 EBITDA loss widens to NOK 7.1 mln

* Q4 revenue 13.1 million Norwegian crowns ($1.53 million) versus 10.0 million crowns year ago

Feb 11 2016

BRIEF-Biotec Pharmacon signs supplier agreement with NutraQ for 2016

* Biotec BetaGlucans AS has signed non-exclusive supplier agreement for production and delivery of betaglucans to nutrition segment with NutraQ AS

Jan 19 2016

BRIEF-Biotec Pharmacon signs deal for Woulgan with Navamedic

* Enters into Nordic distribution agreement for Woulgan with Navamedic

Dec 04 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : GlobalData
$300.00
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00
Provider : GlobalData
$300.00
Provider : GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.